Analyst Rating Update on Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) : 12 analysts are covering Ultragenyx Pharmaceutical (NASDAQ:RARE) and their average rating on the stock is 1.25, which is read as a Strong Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Ultragenyx Pharmaceutical (NASDAQ:RARE) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Ultragenyx Pharmaceutical (NASDAQ:RARE) : Currently there are 11 street experts covering Ultragenyx Pharmaceutical (NASDAQ:RARE) stock. The most bullish and bearish price target for the stock is $125 and $84 respectively for the short term. The average price target of all the analysts comes to $99.64. The estimated standard deviation from the target is $13.74.

For the current week, the company shares have a recommendation consensus of Buy. Also, In the latest statement by the brokerage house, JMP Securities maintains its outlook on Ultragenyx Pharmaceutical (NASDAQ:RARE). The current rating of the shares is Market Outperform, according to the research report released by the firm. The brokerage firm raises the price target from $80 per share to $84 per share. The rating by the firm was issued on June 8, 2016.

Ultragenyx Pharmaceutical (NASDAQ:RARE): stock turned positive on Tuesday. Though the stock opened at $48.49, the bulls momentum made the stock top out at $50.97 level for the day. The stock recorded a low of $48.38 and closed the trading day at $50.73, in the green by 7.34%. The total traded volume for the day was 1,158,129. The stock had closed at $47.26 in the previous days trading.

In an insider trading activity, Agarwal Sunil, (Chief Medical Officer) of Ultragenyx Pharmaceutical Inc., unloaded 650 shares at an average price of $54.16 on June 20, 2016. The total amount of the transaction was worth $35,204, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. Its products are KRN23 (UX023), rhGUS (UX003), rhPPCA (UX004), Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.